Study guide

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice

WHNP-BC Women's Health Nurse Practitioner Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: About the WHNP-BC Exam

WHNP-BC Exam Facts, Blueprint & Study Plan

2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites

4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health

6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis

8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care

7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care

8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy

10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth

9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency

11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

12 Chapter 11: Intrapartum Principles & Fetal Surveillance

11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies

13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications

12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs

14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold

15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders

16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis

17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

18 Chapter 17: Assessment, Diagnostic Testing & Interpretation

17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation

20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice

Key Takeaways Explain This Topic AI

The APRN Consensus Model establishes the LACE framework (Licensure, Accreditation, Certification, Education) standardizing advanced practice nursing across four distinct roles (CNP, CNS, CRNA, CNM) and six core population foci.

State practice authority is classified by the AANP into Full Practice (autonomous evaluation, diagnosis, ordering, and prescribing under the Board of Nursing), Reduced Practice (mandated collaborative agreements), and Restricted Practice (career-long physician supervision or delegation).

Prescribing controlled substances requires both federal DEA registration and state controlled substance credentials; prescribers must routinely consult state Prescription Drug Monitoring Programs (PDMPs) to identify aberrant dispensing patterns and avoid lethal polypharmacy.

Collaborative Practice Agreements (CPAs) in reduced or restricted states must explicitly delineate clinical scope, prescriptive limitations, chart review frequency, emergency backup channels, and formal dispute resolution procedures.

Professional liability coverage differs between occurrence policies (which cover any incident occurring during the active policy period) and claims-made policies (which require tail coverage/extended reporting endorsements upon termination to protect against retroactive claims).

Last updated: October 2026

The APRN Consensus Model & The LACE Framework

The regulation of Advanced Practice Registered Nurses (APRNs) is anchored by the Consensus Model for APRN Regulation: Licensure, Accreditation, Certification, and Education (LACE framework), finalized in 2008 by the National Council of State Boards of Nursing (NCSBN), the American Association of Colleges of Nursing (AACN), and certifying organizations to establish uniform national regulatory standards.

The LACE framework consists of four foundational pillars:

Licensure: Legal authority granted by a State Board of Nursing (BON) to practice as an APRN, requiring an unencumbered RN license, accredited graduate degree, and active national board certification.

Accreditation: Formal evaluation of graduate nursing programs by national bodies (CCNE, ACEN) to ensure curricular and clinical quality.

Certification: Psychometrically sound assessment of clinical competence administered by accredited national certifying bodies. For Women's Health Nurse Practitioners, certification is awarded by the National Certification Corporation (NCC) leading to the WHNP-BC credential.

Education: Formal graduate preparation (MSN, DNP, or post-graduate certificate) incorporating the graduate "3 Ps" (advanced physiology/pathophysiology, advanced pharmacology, and advanced physical assessment) alongside supervised direct patient care hours in the population focus (NCC requires 600 hours for WHNP candidates and 750 for graduates after December 31, 2029).

The Consensus Model recognizes four distinct APRN roles and six population foci:

Four APRN Roles: Certified Nurse Practitioner (CNP), Clinical Nurse Specialist (CNS), Certified Registered Nurse Anesthetist (CRNA), and Certified Nurse-Midwife (CNM).

Six Population Foci: Women's health / gender-related; Family/individual across lifespan; Adult-gerontology (primary or acute care); Pediatrics (primary or acute care); Neonatal; and Psychiatric-mental health.

Specialty credentials (e.g., oncology, maternal-fetal medicine) build upon, but do not replace, the primary population focus.

State Practice Environments: Full, Reduced & Restricted Authority

While the Consensus Model provides a national template, legal scopes of practice are determined by state nurse practice acts. The American Association of Nurse Practitioners (AANP) categorizes state regulatory models into three tiers:

Practice Model Legal Definition & Regulatory Framework Autonomous Scope

Full Practice Authority State licensure laws permit APRNs to evaluate, diagnose, order/interpret diagnostic tests, and initiate/prescribe pharmacologic therapies under the exclusive oversight of the State Board of Nursing. Fully autonomous; no mandated physician supervision or collaborative agreement required.

Reduced Practice Authority State law limits at least one essential element of APRN practice or requires a regulated Collaborative Practice Agreement (CPA) with an outside health discipline (physician) to provide care or prescribe. Practice contingent on an active physician collaborative agreement; may require initial transition-to-practice hours.

Restricted Practice Authority State law restricts APRNs from engaging in at least one practice element, requiring career-long physician supervision, delegation, or direct team management. Operates under delegated physician authority; lowest clinical autonomy.

Important

Practice Authority Trends: The National Academy of Medicine and the Federal Trade Commission (FTC) strongly endorse Full Practice Authority nationwide. Evidence demonstrates full practice authority expands patient access, lowers healthcare costs, and reduces maternity care deserts without compromising clinical safety or quality.

Prescriptive Authority, Controlled Substances & PDMP Compliance

Prescriptive authority is governed by state statute, establishing whether prescribing is independent or delegated. Prescribing controlled substances requires dual federal and state compliance:

DEA Registration: Clinicians prescribing Schedule II–V medications must hold an active federal Drug Enforcement Administration (DEA) registration tied to their state license and practice location.

State Controlled Substance Registration (CSR): Required by many states prior to obtaining or exercising DEA privileges.

Controlled Substance Schedules:

Schedule II: High abuse potential with accepted medical use (e.g., oxycodone, hydrocodone combinations, morphine, methylphenidate); federal law strictly prohibits refills; mandates electronic or tamper-resistant written orders.

Schedule III: Moderate-to-low physical dependence (e.g., buprenorphine, acetaminophen with codeine, testosterone products used in gender-affirming therapy).

Schedule IV: Low abuse potential (e.g., benzodiazepines like diazepam, zolpidem, tramadol).

Schedule V: Lowest abuse liability (e.g., pregabalin, limited-codeine antitussives).

Prescription Drug Monitoring Programs (PDMPs): State electronic registries tracking dispensed controlled substances. Clinicians are statutorily required in most states to query the PDMP before initiating Schedule II–IV substances and periodically during chronic therapy to detect aberrant fills, multiple prescribers, or high morphine milligram equivalents (MME >50 MME/day).

Collaborative Practice Agreements (CPAs)

In reduced and restricted states, APRNs must maintain a formal, signed Collaborative Practice Agreement (CPA) with a licensed physician. Key statutory components include:

Clinical Scope & Protocols: Delineation of patient populations, authorized procedures, and practice settings within the APRN's competencies.

Prescriptive Authority: Defined drug classes, formulary parameters, and specific exclusions for Schedule II–V drugs.

Quality Assurance & Chart Review: Structured schedule and volume for periodic collaborative chart reviews (e.g., 5 to 10 charts or 10% monthly/quarterly).

Emergency Protocols & Backup: Designated communication channels for acute emergencies and patient transfer.

Dispute Resolution & Coverage: Defined coverage during physician absence and mechanisms to resolve clinical management disagreements.

Credentialing & Medical Staff Privileging

National Provider Identifier (NPI): Standard 10-digit identifier mandated by HIPAA. A Type 1 NPI is issued to individual practitioners for direct billing and prescribing; a Type 2 NPI is assigned to organizational entities, clinics, and health systems.

CAQH ProView: Universal repository where clinicians upload verified education, licenses, board certifications, DEA credentials, and malpractice histories for commercial insurer credentialing.

Hospital Privileging: The rigorous institutional peer-review process evaluating verified competencies to grant specific procedural privileges (e.g., colposcopy, endometrial biopsy, IUD placement).

  • Professional Liability, Risk Management & Defensive Documentation
  • Malpractice Insurance Policies

Occurrence Policy: Covers any professional injury occurring during the active policy period, regardless of when the claim is filed. No tail coverage is needed upon departure.

Claims-Made Policy: Covers claims only if the incident occurred and the lawsuit is filed while the policy remains active. Lapses leave clinicians vulnerable to past claims.

Tail Coverage (Extended Reporting Endorsement): Extends the reporting window indefinitely after a claims-made policy ends, protecting clinicians during job changes, relocation, or retirement.

Common Women's Health Liability Claims

Delayed Breast Cancer Diagnosis: The leading liability claim, arising when a clinician fails to order diagnostic ultrasound or biopsy for a dominant palpable breast mass based on a false-negative screening mammogram.

Delayed Cervical Cancer Diagnosis: Failure to track or perform colposcopy following abnormal cytology/hrHPV.

Ectopic Pregnancy Misdiagnosis: Failing to correlate serial quantitative hCG with transvaginal ultrasound, risking tubal rupture.

Fetal Heart Tracing Delays: Delayed intervention for Category III fetal heart rate tracings.

Tip

Defensive Documentation: In malpractice litigation, courts operate on the principle: "If it was not documented, it was not done." Maintain contemporaneous, objective charting; document detailed informed consent and informed refusal discussions; record telephone triage and red-flag return precautions; and maintain reliable tracking systems for all diagnostic results.